Literature DB >> 8126463

Large-scale production and characterization of recombinant human immunodeficiency virus type 1 Nef.

A A Azad1, P Failla, A Lucantoni, J Bentley, C Mardon, A Wolfe, K Fuller, D Hewish, S Sengupta, S Sankovich.   

Abstract

Sequences encoding the 27K and 25K nef gene products (Nef 27 and Nef 25) were amplified by PCR from a human immunodeficiency virus type 1 infectious clone and subcloned directly into Escherichia coli, yeast and baculovirus expression vectors. The yeast- and baculovirus-derived Nef had native N termini but the expression levels were low. The expression levels of the E. coli-derived glutathione S-transferase-Nef fusion proteins were very high and a major portion was soluble. Large-scale production of E. coli-derived Nef 27 and Nef 25 was carried out by growing recombinant cells in a fermenter under fed-batch conditions followed by affinity purification on glutathione-Sepharose before and after thrombin cleavage. Large quantities of highly purified recombinant Nef proteins have been produced for functional and structural studies. Under non-reducing conditions both Nef 27 and Nef 25 existed as a mixture of monomers, dimers and small amounts of higher oligomers, but when reduced were monomeric. The highly purified Nef proteins had no G protein activities, however Nef 27 was biologically active. When electroporated into uninfected CD4+ T lymphocytes both E. coli-derived Nef 27 and yeast-derived myristylated Nef 27 down-regulated the surface expression of CD4, demonstrating that this method can be used to assess the biological activity of purified recombinant Nef.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126463     DOI: 10.1099/0022-1317-75-3-651

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

Review 1.  Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Authors:  Ryan P Staudt; John J Alvarado; Lori A Emert-Sedlak; Haibin Shi; Sherry T Shu; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-08-29       Impact factor: 5.157

2.  Simian immunodeficiency virus and human immunodeficiency virus type 1 nef proteins show distinct patterns and mechanisms of Src kinase activation.

Authors:  A L Greenway; H Dutartre; K Allen; D A McPhee; D Olive; Y Collette
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat.

Authors:  D G Smith; G J Guillemin; L Pemberton; S Kerr; A Nath; G A Smythe; B J Brew
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

4.  Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis.

Authors:  Alison L Greenway; Dale A McPhee; Kelly Allen; Ricky Johnstone; Gavan Holloway; John Mills; Ahmed Azad; Sonia Sankovich; Paul Lambert
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines.

Authors:  A Greenway; A Azad; D McPhee
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity.

Authors:  A Greenway; A Azad; J Mills; D McPhee
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

7.  Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells.

Authors:  Carla Marusic; James Nuttall; Giampaolo Buriani; Chiara Lico; Raffaele Lombardi; Selene Baschieri; Eugenio Benvenuto; Lorenzo Frigerio
Journal:  BMC Biotechnol       Date:  2007-02-26       Impact factor: 2.563

Review 8.  Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study.

Authors:  Carla Marusic; Alessandro Vitale; Emanuela Pedrazzini; Marcello Donini; Lorenzo Frigerio; Ralph Bock; Philip J Dix; Matthew S McCabe; Michele Bellucci; Eugenio Benvenuto
Journal:  Transgenic Res       Date:  2009-01-25       Impact factor: 2.788

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.